Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|
EPS | $1.0 | $0.9 | $3.4 | $3.9 | $6.4 | $1.3 | $1.2 | $0.1 | $3.4 |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Royalty Pharma plc's last 12-month EPS is $3.0, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Royalty Pharma plc's EPS growth was 5,821.2%. The average annual EPS growth rates for Royalty Pharma plc have been 25.4% over the past three years, 2.5% over the past five years.
Over the last year, Royalty Pharma plc's EPS growth was 5,821.2%, which is higher than industry growth of (0.1%). It indicates that Royalty Pharma plc's EPS growth is Good.